Best of the Brokers for 13 November 2014

To appear in Best of the Brokers, email your research to

Jefferies reiterated its “buy” rating, citing a compelling growth story. The broker noted that BTG’s varicose vein drug Varithena was moving at a steady pace, with encouraging numbers around sales and brand awareness. Target price was bumped up to 875p from 760p.

Shore Capital reiterated its “buy” rating, saying the construction firm’s interim management statement had been the “most positive” so far in this season, with “no planning or cost issues highlighted”. The broker’s fair estimate value moved from 136p to 148p.